Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Nasopharyngitis, SARS-CoV-2 test
Clinical narrative: Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like; Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) and NASOPHARYNGITIS (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 065F21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Allergic to demerol.). Concomitant products included PRAVASTATIN for an unknown indication.   On 13-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Jan-2022, the patient experienced COVID-19 (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) and NASOPHARYNGITIS (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like). The patient was treated with AZITHROMYCIN (ZITHROMAX) at an unspecified dose and frequency and GUAIFENESIN (MUCINEX) at an unspecified dose and frequency. At the time of the report, COVID-19 (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) and NASOPHARYNGITIS (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Jan-2022, SARS-CoV-2 test: positive (Positive) Positive.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered COVID-19 (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) and NASOPHARYNGITIS (Lack of efficacy Received a RT-PCR report with a positive diagnosis of COVID-19 and have cold-like) to be related.    Company comment:This case concerns 43-years-old, male patient with no reported medical history, who experienced the unexpected AESI event of Covid-19. The event occurred approximately 4 days before to the third dose of mRNA-1273 vaccine(07-Jan-2022). Reportedly, SARS-CoV-2 test was  positive(03-Jan-2022). Patient received treatment with AZITHROMYCIN and GUAIFENESIN. At the time of the report the outcome of the event was not resolved. The case was assessed as nonserious as per Regulatory Authority's report. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 07-Jan-2022: Follow-up received includes reporter type, reporter occupation, and event updated.; Sender's Comments: This case concerns 43-years-old, male patient with no reported medical history, who experienced the unexpected AESI event of Covid-19. The event occurred approximately 4 days before to the third dose of mRNA-1273 vaccine(07-Jan-2022). Reportedly, SARS-CoV-2 test was  positive(03-Jan-2022). Patient received treatment with AZITHROMYCIN and GUAIFENESIN. At the time of the report the outcome of the event was not resolved. The case was assessed as nonserious as per Regulatory Authority's report. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.